LONG BEACH CA--(Marketwired - September 29, 2017) - The Translational Pulmonary Immunological Research Center (TPIRC), a progressive research, clinical care and patient advocacy center created to advance the treatment of orphan diseases, has announced the appointment of Jon C. Wolfe as its new President of the Board of Directors. In his new role, Wolfe will be responsible for the general supervision, direction and control of the institute's business endeavors. Reporting to Dr. Inderpal Randhawa, Chairman of the Board, Wolfe will also partner with Dr. Randhawa to help guarantee that the entirety of TPIRC's directives, policies and resolutions are carried out.

TPIRC is a 501(c)(3) nonprofit corporation and a rare disease institute combining basic research, cutting-edge clinical care, disease education and awareness and philanthropy under one roof. Located in Long Beach, CA next to Miller's Children's Hospital, TPIRC's research is focused on five orphan conditions: Food Allergy and Intolerance, Adult Cystic Fibrosis, Bronchiectasis, Immunodeficiency, and Airway Inflammatory Disorders.
Although each affects patients differently, concentrating on all five conditions at the research center allows patient populations to be locally cared for in the hospital adjacent to TPIRC, enhances impact by sharing research, medical and advocacy workforce costs and drives improved research discovery and clinical care models thanks to a safe, diverse and collaborative environment shared with local universities and laboratories.

"We are so excited to have Jon join our board as President," said Dr. Randhawa. "As President and CEO of House Advantage and Entourage Investment Group, Jon and his companies are industry leaders and Jon is known in many business circles for his forward strategic thinking, first-rate results and an unrelenting quest for perfection. It is that unmatched skill set Jon has that TPIRC needs and which will be immensely beneficial going forward. We can't wait to see where our new partnership leads us and the successes we bring to TPIRC overall," concluded Randhawa.

"I am very honored to be working with Dr. Randhawa and his entire team on the future of TPIRC," said Wolfe. "They have developed an incredible model with an unsurpassed legacy of success. To be able to support the wider proliferation and expansion of their previous success is a tremendous personal mission for me and among the first of many things I look to accomplish through immediately developing, implementing and monitoring standard business practices while always focusing on extensive fundraising operations.

Cardiology Homepage